Compare · ARGX vs IMVT
ARGX vs IMVT
Side-by-side comparison of argenx SE (ARGX) and Immunovant Inc. (IMVT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and IMVT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 6.5x IMVT ($8.27B).
- IMVT has been more active in the news (12 items in the past 4 weeks vs 3 for ARGX).
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Immunovant Inc.
- Price
- -
- -
- Market cap
- $53.41B
- $8.27B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2019
- News (4w)
- 3
- 12
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Immunovant Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest IMVT
- Chief Operating Officer Gloria Melanie sold $80,532 worth of shares (2,036 units at $39.55), decreasing direct ownership by 0.91% to 222,357 units (SEC Form 4) to satisfy withholding tax
- Chief Legal Officer Van Tuyl Christopher sold $47,702 worth of shares (1,206 units at $39.55), decreasing direct ownership by 0.67% to 179,391 units (SEC Form 4) to satisfy withholding tax
- Chief Technology Officer Stout Jay S sold $137,925 worth of shares (3,487 units at $39.55), decreasing direct ownership by 2% to 208,198 units (SEC Form 4) (tax withholding)
- Chief Executive Officer Venker Eric sold $118,980 worth of shares (3,092 units at $38.48), exercised 92,188 shares at a strike of $14.46 and returned $3,304,030 worth of shares to the company (86,629 units at $38.14), increasing direct ownership by 0.98% to 254,280 units (SEC Form 4) (withholding obligation)
- Chief Operating Officer Gloria Melanie sold $678,604 worth of shares (17,714 units at $38.31), decreasing direct ownership by 7% to 224,393 units (SEC Form 4)
- Chief Technology Officer Stout Jay S sold $1,532,309 worth of shares (40,000 units at $38.31), decreasing direct ownership by 16% to 211,685 units (SEC Form 4)
- Chief Legal Officer Van Tuyl Christopher exercised 17,824 shares at a strike of $15.20 and sold $682,887 worth of shares (17,824 units at $38.31) (SEC Form 4)
- Chief Financial Officer Girao Tiago exercised 10,000 shares at a strike of $15.90 and sold $384,600 worth of shares (10,000 units at $38.46) (SEC Form 4)
- Director Pande Atul exercised 1,500 shares at a strike of $8.43 and sold $57,015 worth of shares (1,500 units at $38.01) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Immunovant Inc.